Global stock

NASDAQUSD

NovoCure Ltd.

NVCR

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

52/ 100

Overall score·NVCR

Current price

14.77USD

23/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Růst tržeb o 15,6 % a cílová cena analytiků nad aktuální cenou podporují růstový výhled, avšak společnost zůstává ztrátová a záporné forward P/E i EV/EBITDA ztěžují tradiční ocenění. P/B kolem 5 a nejistota klinického vývoje oslabují hodnocení hodnoty; relativně příznivými stránkami jsou běžná likvidita 2,89 a cena nad 200denním průměrem.

§ Outlook vs S&P 500Next 12 months

About the same

Estimated chance of beating the index: about 54%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Context and events

Management

Executive Chairman William F. Doyle a CEO a člen představenstva Frank Leonard vedou společnost zaměřenou na vývoj a rozšiřování léčby nádorů pomocí TTFields. Finanční řízení má na starosti CFO Christoph Brackmann; strategickým cílem je rozvíjet klinické využití technologie a její komerční dosah.

Articles about NovoCure Ltd., in Czech (1)

Novocure získává certifikát CE pro léčbu pokročilého karcinomu slinivky břišní s Optune Pax®

Společnost Novocure oznámila, že její zařízení Optune Pax® obdrželo certifikát CE, který umožňuje jeho použití při léčbě lokálně pokročilého karcinomu slinivky břišní. Tento krok rozšiřuje možnosti terapie této závažné onkologické diagnózy v Evropě.

6 July 2026· 3 min

§ Upcoming results

29 October 2026

in 2 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is NovoCure Ltd. (NVCR)?

NovoCure Ltd. (NVCR) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the NovoCure Ltd. price today?

As of 23 October 2026, NovoCure Ltd. trades at about 14.77 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy NovoCure Ltd.?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does NovoCure Ltd. pay a dividend?

NovoCure Ltd. either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is NovoCure Ltd. a good investment in 2026?

Our AI signal currently rates NovoCure Ltd. as neutral (score 49/100). Financial health comes out at 52/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy NovoCure Ltd.

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Neutral

Earnings in 2 days

On 29 October 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

No newer news

Signal 12/10, 11:31

Zpráva 10. října 2026 uvádí, že japonské schválení Optune Pax pro léčbu rakoviny slinivky může změnit investiční výhled NovoCure. Schválení může podpořit vnímání obchodního potenciálu, jeho trvalý dopad však závisí na tom, zda se promítne do širšího využití a výsledků společnosti.

Zpráva má mírně pozitivní tón, ale cenový vývoj je slabý: NVCR za posledních 7 dní klesl o 2,41 % a za 30 dní o 5,02 %. Klesající trend, momentum 25 a RSI 31 potvrzují krátkodobý tlak, přestože RSI je blízko přeprodané oblasti. Vysoká volatilita zvyšuje nejistotu a dostupné podklady nestačí k přesvědčivému závěru o střednědobé stabilitě.

Risks: Pokračující pokles ceny nebo neúspěch proměnit schválení v širší využití by oslabil pozitivní interpretaci zprávy. Naopak obrat trendu a trvalejší zlepšení obchodních výsledků by zmírnily současný krátkodobě negativní signál.

More about the signal

Signal history· 2

05/1015:0136 · Slightly negative
NovoCure po zřetelném cenovém poklesu zůstává na ceně kolem 15 USD; technická konvergence naznačuje nejistotu, rally se zatím nedostavuje. Makro prostředí EUR/CZK a USD/CZK zůstává nadále neutrální.
29/0910:3032 · Slightly negative
Nová zpráva naznačuje omezený krátkodobý výhled pro NovoCure, makro kontext naznačuje tlak na techniku ve světle poklesu ceny a vysoké volatility.

The full 90-day signal history is part of Premium.

Ask the AI

DCF valuation

A DCF model is not suitable for this asset class.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 15 of 18

Valuation score

2/ 6

2/6 tests available

1. Below DCF fair value

The complete DCF range or the current price is missing.

2. Well below DCF value

The complete DCF range or the current price is missing.

3. Price vs. the last year

48% above the 1-year low (10.03 USD to 19.99 USD), based on stored daily prices.

4. P/E vs. similar companies

The sector sample has only 72 companies; scoring needs at least 8.

5. P/E relative to growth

PEG or a reliable growth input is not available.

6. Analyst price target

81.9% vs. the current price, 7 analysts.

Price and fair value

no complete range

The DCF check appears once both the price and the model range are available.

Price vs analyst target

Current price

14.77 USD

Low 17.00 USDHigh 52.00 USD

Current priceAverage: 26.86 USD

DCF gap

no complete range

The DCF check appears once both the price and the model range are available.

Analyst target

+81.9%

Average target 26.86 USD vs. price 14.77 USD.

Analyst consensus

Target range

17.00 USD - 52.00 USD

Coverage

7 analysts

Analyst consensus

Changes 180 d

+0 / -0

EPS next year

34.7%

Revenue next year

10.8%

Valuation multiples

-18.3

5.1

2.5

-11.4

52-week range48% above the low

10.03 USD19.99 USD

16.0%

-21.3%

-43.2%

Price vs 50D-8.9%

Price vs 200D-0.3%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení rozvíjí klinické programy a komercializaci TTFields, ale přetrvávající ztráty a rizika exekuce klinických i partnerských programů snižují hodnocení.

strong

Vlastní TTFields technologie a její klinické i komerční využití vytvářejí potenciální výhodu, kterou však omezují nejistota rozšíření indikací a konkurence alternativní léčby.

Information

Type: Global stock
Symbol: NVCR
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 1.7B USD
: 69.0 %
: 0.99

§ Risk profile

Výsledek investice závisí na klinických důkazech, regulatorních rozhodnutích a ochotě nemocnic, pacientů a pojišťoven léčbu TTFields využívat a hradit. České výnosy navíc ovlivňuje kurz dolaru vůči koruně.

Ask the AI about NovoCure Ltd.All signals